This content was originally published on CGTLive, a sister publication. Click here to view the original content.
According to a recent announcement, the FDA accepted and granted priority review to Sarepta Therapeutics’ biologics license application (BLA) for SRP-9001, an investigative gene therapy for treating Duchenne muscular dystrophy (DMD), with a PDUFA date set for May 29, 2023.1
"We are delighted to announce that the FDA has accepted Sarepta’s BLA for SRP-9001 for filing and priority review," Doug Ingram, president and chief executive officer, Sarepta Therapeutics, said in a statement.1 "Duchenne is a relentlessly degenerative and invariably fatal disease, robbing children of muscle and function hourly and daily. Our BLA submission for an accelerated approval, along with the FDA’s acceptance of that BLA for filing and review, is a tremendously important milestone in our effort to bring a potentially life-changing gene therapy to Duchenne patients as rapidly as possible and we look forward to working with the FDA through the review process."
Developed in partnership with Roche, SRP-9001 is designed to express microdystrophin to combat the deleterious effects of the dysfunctional dystrophin produced in DMD. It has been granted fast track, rare pediatric, and orphan drug designations in the US as well as orphan drug status in the EU, Switzerland, and Japan. Of note, the BLA was submitted using the accelerated approval pathway in September 2022.2